You have 9 free searches left this month | for more free features.

Janus kinase (JAK)

Showing 1 - 25 of 2,287

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Janus Kinase Inhibitors Vs Tumor Necrosis Factor Inhibitors in

Not yet recruiting
  • Rheumatoid Arthritis
  • Observation
  • (no location specified)
Oct 8, 2022

Diabetes, Type 1 Trial (Abrocitinib 200 MG Oral Tablet, Ritlecitinib, Placebo)

Not yet recruiting
  • Diabetes Mellitus, Type 1
  • Abrocitinib 200 MG Oral Tablet
  • +2 more
  • (no location specified)
Feb 21, 2023

Abatacept, Treatment Compliance, Rheumatoid Arthritis Trial in Hangzhou (Janus Kinase Inhibitor, Abatacept)

Recruiting
  • Abatacept
  • +2 more
  • Hangzhou, Zhejiang, China
    Zhejiang Provincial People's Hospital
Jul 5, 2022

Alopecia Areata Trial in Sohag (Janus Kinase 1 and 2)

Recruiting
  • Alopecia Areata
  • Janus Kinase 1 and 2
  • Sohag, Egypt
    Sohag University hospitals
May 12, 2023

Sarcoidosis Trial in New Haven (Abrocitinib 200 mg)

Not yet recruiting
  • Sarcoidosis
  • Abrocitinib 200 mg
  • New Haven, Connecticut
    Yale University
Jan 24, 2023

Granuloma Annulare Trial in New Haven (Abrocitinib 200 mg)

Not yet recruiting
  • Granuloma Annulare
  • Abrocitinib 200 mg
  • New Haven, Connecticut
    Yale University
Dec 19, 2022

Myelofibrosis Trial in Worldwide (Imetelstat 4.7 mg/kg, Imetelstat 9.4 mg/kg)

Completed
  • Myelofibrosis
  • Imetelstat 4.7 mg/kg
  • Imetelstat 9.4 mg/kg
  • Birmingham, Alabama
  • +71 more
Aug 17, 2021

Sjogren's Syndrome Trial run by the National Institute of Dental and Craniofacial Research (NIDCR) (tofacitinib, Placebo)

Recruiting
  • Sjogren's Syndrome
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Nov 24, 2022

Janus Kinase Inhibitor Therapy in Ulcerative Colitis

Terminated
  • Ulcerative Colitis
  • Janus Kinase Inhibitor
  • Amsterdam, North Halland, Netherlands
    Amsterdam Medical Center, IBD Center
Dec 14, 2021

Idiopathic Inflammatory Myopathies Trial in Beijing (tofacitinib)

Recruiting
  • Idiopathic Inflammatory Myopathies
  • Beijing, Beijing, China
    Department of Rheumatology and Immunology, Peking University Peo
Oct 9, 2022

Lupus or SLE, Nephritis Trial in Assiut (Baricitinib 4 MG, Baricitinib 2 MG, MMF)

Recruiting
  • Lupus or SLE
  • Nephritis
  • Baricitinib 4 MG
  • +2 more
  • Assiut, Yes, Egypt
    Manal Hassanien
Jan 13, 2023

Chronic Kidney Diseases Trial in Durham (Baricitinib, Placebo)

Recruiting
  • Chronic Kidney Diseases
  • Durham, North Carolina
    Duke Research at Pickett Road
Dec 15, 2022

Myelofibrosis Trial in Worldwide (Imetelstat, Best Available Therapy (BAT))

Recruiting
  • Myelofibrosis
  • La Jolla, California
  • +165 more
Aug 19, 2022

Lupus Nephritis Trial in Assiut (Anti JAK1,2)

Active, not recruiting
  • Lupus Nephritis
  • Anti JAK1,2
  • Assiut, Assuit, Egypt
    Manal Hassanien
Jun 21, 2022

JAK-STAT Signaling Pathway in Pyoderma Gangrenosum

Not yet recruiting
  • Pyoderma Gangrenosum
  • +2 more
  • immunohistochemical methods
  • (no location specified)
Mar 21, 2022

Rheumatoid Arthritis Trial in London (Etanercept, tofacitinib)

Recruiting
  • Rheumatoid Arthritis
  • London, Ontario, Canada
    Rheumatology Clinic, St. Joseph's Health Care
May 10, 2022

JAK Inhibition in Ulcerative Colitis

Not yet recruiting
  • Analyzing Immune Composition Changes Upon JAK Inhibitor Treatment of Ulcerative Colitis Patients
  • JAK inhibitor treatment
  • (no location specified)
Jul 11, 2022

Acneiform Eruptions Trial in Shanghai (Cream containing JAK Inhibitor)

Recruiting
  • Acneiform Eruptions
  • Cream containing JAK Inhibitor
  • Shanghai, Shanghai, China
    Shanghai East Hospital
Jun 20, 2022

COVID-19 Trial in Halifax (Baricitinib (janus kinase inhibitor), Remdesivir (antiviral) + barictinib (janus kinase inhibitor),

Recruiting
  • COVID-19
  • Baricitinib (janus kinase inhibitor)
  • +3 more
  • Halifax, Nova Scotia, Canada
    Nova Scotia Health Authority
Mar 9, 2022

Head and Neck Squamous Cell Carcinoma Trial in Tucson, San Francisco (Ruxolitinib)

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Tucson, Arizona
  • +1 more
Sep 22, 2022

Vitiligo, Generalized Trial (Baricitinib)

Not yet recruiting
  • Vitiligo, Generalized
  • (no location specified)
Jul 7, 2023

Cutaneous Sarcoidosis, Granuloma Annulare Trial in New Haven (Tofacitinib 5 mg twice daily)

Completed
  • Cutaneous Sarcoidosis
  • Granuloma Annulare
  • Tofacitinib 5 mg twice daily
  • New Haven, Connecticut
    Yale Center for Clinical Investigation
Jul 13, 2021

Ruxolitinib in Patients With Myelofibrosis

Not yet recruiting
  • Myelofibrosis
  • (no location specified)
Feb 28, 2023

Inpatient COVID-19 Treatments

Active, not recruiting
  • COVID-19
  • Initiation of IL6Ri (tocilizumab or sarilumab) versus JAKi (baricitinib or tofacitinib) added to systemic corticosteroids of interest (CSI)
  • New York, New York
    Aetion, Inc.
Jan 12, 2023

Non-sclerotic Cutaneous Chronic Graft-versus-host Disease Trial in New York (topical ruxolitinib 1.5% cream, Topical

Recruiting
  • Non-sclerotic Cutaneous Chronic Graft-versus-host Disease
  • topical ruxolitinib 1.5% cream
  • Topical vehicle/moisturizer cream
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Dec 20, 2022